Niriella Madunil Anuk, Dassanayake Uditha, de Silva H Janaka
Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(9):913-919. doi: 10.1080/17474124.2023.2255515. Epub 2023 Sep 7.
Hepatocellular carcinoma (HCC) is the most common liver-related cancer and the third leading cause of worldwide cancer-related mortality.
There have been many updated guidelines on the management of HCC in the past few years. Given the increasing burden of HCC in clinical practice, knowledge of evidence-based standards of care for these patients is essential for any practitioner managing patients with HCC. Early detection and judicious treatment based on the stage of the HCC can improve patient outcomes. We performed a PubMed (MEDLINE database) search for the latest guidelines related to the screening, detection, diagnosis, staging, and management of HCC. We aim to highlight some major considerations and common mistakes in managing HCC and attempt to provide evidence-based recommendations.
The field of HCC management is expected to evolve in the coming years. Increased emphasis on personalized treatment and precision medicine with earlier detection methods, the development of noninvasive diagnostic tools, increased focus on combination therapies and a shift toward more targeted treatments will become more critical.
肝细胞癌(HCC)是最常见的肝脏相关癌症,也是全球癌症相关死亡的第三大主要原因。
在过去几年里,出现了许多关于HCC管理的更新指南。鉴于HCC在临床实践中的负担日益加重,对于任何管理HCC患者的从业者而言,了解这些患者基于证据的标准治疗方法至关重要。早期检测以及根据HCC的阶段进行明智的治疗可改善患者预后。我们在PubMed(医学文献数据库)中搜索了与HCC的筛查、检测、诊断、分期和管理相关的最新指南。我们旨在强调HCC管理中的一些主要考虑因素和常见错误,并尝试提供基于证据的建议。
预计未来几年HCC管理领域将会发展。更加注重个性化治疗和精准医学,采用更早的检测方法,开发非侵入性诊断工具,更加关注联合疗法以及向更具针对性的治疗转变将变得更加关键。